Table 2.
Baseline data for RESAFE‐HF endpoints
| Variable |
All patients N = 106 |
|---|---|
| Iron‐related primary outcome | |
|
Iron RESAFE composite (%) Fer ≥ 100 mL, Hb ≥ 12 g/dL, TSAT ≥ 20% |
1 (0.9%) |
|
ESC iron composite (%) Fer ≥ 300 ng/mL or Fer ≥ 100 ng/mL and TSAT ≥ 20% |
0 (0%) |
| Haemoglobin (g/dL) | 12.8 ± 1.53 |
| TSAT (%) | 18.8 (10.3) |
| Ferritin (ng/mL) | 55.4 (64) |
| CIED‐derived arrhythmic outcomes | |
|
VT/VF episodes (year−1) (10% trimmed mean ± SD) |
0.58 ± 3.05 |
|
nsVT episodes (year−1) (10% trimmed mean ± SD) |
5.22 ± 100 |
|
Appropriate shocks (year−1) (5% trimmed mean ± SD) |
0.17 ± 0.58 |
|
Appropriate therapies (year−1) (5% trimmed mean ± SD) |
0.44 ± 1.43 |
|
Days in AF last year (AF only) |
65 (365) |
| Holter‐derived arrhythmic outcomes | |
| Lown and Wolf classification | |
| 0 | 0 (0%) |
| 1 | 18 (17%) |
| 2 | 5 (4.7%) |
| 3 | 3 (2.8%) |
| 4a | 30 (28.3%) |
| 4b | 29 (27.4%) |
| 5 | 21 (19.8%) |
| Ultrasonographic outcomes | |
| LVEDVi (mm3/m2) | 92.5 (39) |
| LVEF (%) | 28.8 ± 7.6 |
| LV GLS (%) | −7.9 (3.9) |
| Functional outcomes | |
| Peak VO2 (mL/kg/min) (n = 95) | 11.1 ± 3.1 |
| VE/VCO2 slope (n = 95) | 37 (11) |
| PetCO2 (mmHg) (n = 95) | 32 (10) |
| 6MWD (m) (n = 97) | 421.3 (126) |
| Biomarker outcomes | |
| BNP (pg/mL) | 354.5 (506) |
| NT‐proBNP (pg/mL) | 777 (2424) |
| QoL outcomes | |
| KCCQ total score (%) | 65.8 (29) |
| EQ‐5D‐5L VAS (%) | 60 (20) |
6MWD, 6 min walk distance; AF, atrial fibrillation; BNP, brain natriuretic peptide; CIED, cardiac implantable electronic device; EQ‐5D‐5L VAS, EQ‐5D‐5L visual association scale; ESC, European Society of Cardiology; Fer, ferritin; Hb, haemoglobin; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV GLS, left ventricular global longitudinal strain; LVEDVi, left ventricular end‐diastolic volume index; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; PetCO2, partial pressure of end‐tidal carbon dioxide; QoL, quality of life; SD, standard deviation; TSAT, transferrin saturation; VE/VCO2 slope, minute ventilation/carbon dioxide production; VF, ventricular fibrillation; VO2, oxygen consumption; VT, ventricular tachycardia.